Abstract
The treatment of patients with good performance status and advanced stage non-small cell lung cancer has been based on the use of first-line platinum-based doublet and second-line docetaxel. Immunotherapy represents a new therapeutic approach with the potential for prolonged benefit. Although the vaccines studied have not shown benefit in patients with non-small cell lung cancer, immune checkpoint inhibitors against the PD-1/PD-L1 axis showed increased overall survival compared with docetaxel in randomized clinical trials, which led to the approval of nivolumab and pembrolizumab. Because only a minority of patients benefit from this class of drugs, there has been an intense search for biomarkers.
Keywords:
Immune checkpoint inhibitors; Non–small cell lung cancer; PD-L1; Vaccines.
Copyright © 2016 Elsevier Inc. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
B7-H1 Antigen / antagonists & inhibitors
-
B7-H1 Antigen / metabolism
-
Disease-Free Survival
-
Docetaxel
-
Humans
-
Immunotherapy / methods*
-
Lung Neoplasms / metabolism
-
Lung Neoplasms / mortality
-
Lung Neoplasms / therapy*
-
Neoplasm Proteins / therapeutic use
-
Nivolumab
-
Platinum Compounds / therapeutic use
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / metabolism
-
Survival Rate
-
Taxoids / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
B7-H1 Antigen
-
CD274 protein, human
-
Neoplasm Proteins
-
PDCD1 protein, human
-
Platinum Compounds
-
Programmed Cell Death 1 Receptor
-
Taxoids
-
Docetaxel
-
Nivolumab
-
pembrolizumab